Get the latest news, insights, and market updates on DXCM (DexCom, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
A Look At Dexcom (DXCM) Valuation After Recent Share Price Swings
Without a specific news headline driving the move, DexCom (DXCM) sits at a recent close of US$70.69, leaving investors weighing its continuous glucose monitoring business against recent share price swings over the month and the past 3 months. See our latest analysis for DexCom. That recent dip sits within a mixed picture, with a 7 day share price return of 5.0% and a 90 day share price return of 7.9%, contrasting with a 1 year total shareholder return decline of 11.1%. This suggests near term... Mar 6, 2026 - $DXCM
Is DexCom Stock Underperforming the Nasdaq?
DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s future. Mar 5, 2026 - $DXCM
1 Nasdaq 100 Stock with Impressive Fundamentals and 2 We Avoid
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that could limit future upside. Mar 3, 2026 - $DXCM
DexCom Weighs GLP 1 CGM Tailwind Against Valuation And Momentum Signals
DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care. The company is refining its product lineup, with management expecting the 15 day G7 CGM system to take a leading role within its portfolio. These developments are material for investors because they relate to DexCom's growth paths across domestic and international CGM markets beyond standard earnings... Feb 26, 2026 - $DXCM
Aristotle Growth Equity Fund Bets on DexCom (DXCM) Due to Its Expanding CGM Market Leadership
Aristotle Funds, an investment advisor, released its “Growth Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets reached new all-time highs in Q4 2025, with the S&P 500 Index rising 2.66% and the Bloomberg U.S. Aggregate Bond Index increasing by 1.10%. Within the Russell 1000 Growth Index, […] Feb 26, 2026 - $DXCM
Mizuho Raises DexCom (DXCM) Price Target to $90 from $78 After Earnings Beat
We recently published an article titled 13 Best Internet of Things (IoT) Stocks to Buy Now. On February 13, Mizuho analyst Anthony Petrone raised the price target on DexCom, Inc. (NASDAQ:DXCM) to $90 from $78 while maintaining an Outperform rating, citing a favorable post-earnings setup following a quarterly beat that exceeded expectations. The previous day, […] Feb 25, 2026 - $DXCM
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO, February 25, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. Feb 25, 2026 - $DXCM
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple